FDA approves Global Blood Therapeutics's sickle cell disease drug

The U.S. Food and Drug Administration said on Monday that it had approved Global Blood Therapeutics’s drug, Oxbryta, to treat sickle cell disease in adults and pediatric patients aged 12 years or older.